Meridian Bioscience, Inc is a diagnostics & research business based in the US. Meridian Bioscience shares (VIVO) are listed on the NASDAQ and all prices are listed in US Dollars. Meridian Bioscience employs 750 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Meridian Bioscience
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – VIVO – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- VIVO shares summary
- Compare share dealing platforms
- Is VIVO stock a buy or sell?
- Stock performance over time
- Can I short VIVO shares?
- Are VIVO shares over-valued?
- Meridian Bioscience's financials
- How volatile are VIVO shares?
- Does Meridian Bioscience pay a dividend?
- Have VIVO shares ever split?
- Other common questions
Meridian Bioscience stock price (NASDAQ: VIVO)Use our graph to track the performance of VIVO stocks over time.
Meridian Bioscience shares at a glance
|Latest market close||$21.11|
|52-week range||$12.98 - $30.65|
|50-day moving average||$20.34|
|200-day moving average||$22.18|
|Wall St. target price||$29.67|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$2.00|
Buy Meridian Bioscience shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Meridian Bioscience stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Meridian Bioscience price performance over time
|1 week (2021-07-20)||N/A|
|1 month (2021-07-01)||-6.01%|
|3 months (2021-04-30)||7.81%|
|6 months (2021-01-27)||N/A|
|1 year (2020-07-27)||N/A|
|2 years (2019-07-27)||N/A|
|3 years (2018-07-27)||N/A|
|5 years (2016-07-27)||N/A|
Is Meridian Bioscience under- or over-valued?
Valuing Meridian Bioscience stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Meridian Bioscience's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Meridian Bioscience's P/E ratio
Meridian Bioscience's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 10x. In other words, Meridian Bioscience shares trade at around 10x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Meridian Bioscience's PEG ratio
Meridian Bioscience's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.33. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Meridian Bioscience's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Meridian Bioscience's EBITDA
Meridian Bioscience's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $126.7 million.
The EBITDA is a measure of a Meridian Bioscience's overall financial performance and is widely used to measure a its profitability.
Meridian Bioscience financials
|Revenue TTM||$327.1 million|
|Operating margin TTM||34.12%|
|Gross profit TTM||$156.2 million|
|Return on assets TTM||18.4%|
|Return on equity TTM||33.88%|
|Market capitalisation||$896.1 million|
TTM: trailing 12 months
Shorting Meridian Bioscience shares
There are currently 4.8 million Meridian Bioscience shares held short by investors – that's known as Meridian Bioscience's "short interest". This figure is 1.4% down from 4.9 million last month.
There are a few different ways that this level of interest in shorting Meridian Bioscience shares can be evaluated.
Meridian Bioscience's "short interest ratio" (SIR)
Meridian Bioscience's "short interest ratio" (SIR) is the quantity of Meridian Bioscience shares currently shorted divided by the average quantity of Meridian Bioscience shares traded daily (recently around 544344.87034949). Meridian Bioscience's SIR currently stands at 8.87. In other words for every 100,000 Meridian Bioscience shares traded daily on the market, roughly 8870 shares are currently held short.
However Meridian Bioscience's short interest can also be evaluated against the total number of Meridian Bioscience shares, or, against the total number of tradable Meridian Bioscience shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Meridian Bioscience's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Meridian Bioscience shares in existence, roughly 110 shares are currently held short) or 0.1119% of the tradable shares (for every 100,000 tradable Meridian Bioscience shares, roughly 112 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Meridian Bioscience.
Find out more about how you can short Meridian Bioscience stock.
Meridian Bioscience share dividends
We're not expecting Meridian Bioscience to pay a dividend over the next 12 months.
Have Meridian Bioscience's shares ever split?
Meridian Bioscience's shares were split on a 3:2 basis on 13 May 2007. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Meridian Bioscience shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Meridian Bioscience shares which in turn could have impacted Meridian Bioscience's share price.
Meridian Bioscience share price volatility
Over the last 12 months, Meridian Bioscience's shares have ranged in value from as little as $12.98 up to $30.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Meridian Bioscience's is 0.4853. This would suggest that Meridian Bioscience's shares are less volatile than average (for this exchange).
Meridian Bioscience overview
Meridian Bioscience, Inc. , a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare and PediaStat brands; and urea breath testing for H. pylori under the BreathID brand. This segment also offers gastrointestinal assays, including tests for C. difficile, H.
Stocks similar to Meridian Bioscience
Meridian Bioscience in the news
Hedge Funds Aren’t Crazy About Meridian Bioscience, Inc. (VIVO) Anymore
Meridian To Buy Urea Breath Test For H. Pylori From Otsuka America Pharmaceutical For $20M
Meridian Signs Definitive Agreement to Acquire Urea Breath Test for H. pylori from Otsuka America Pharmaceutical, Inc.
Frequently asked questionsWhat percentage of Meridian Bioscience is owned by insiders or institutions?
Currently 0.543% of Meridian Bioscience shares are held by insiders and 98.911% by institutions. How many people work for Meridian Bioscience?
Latest data suggests 750 work at Meridian Bioscience. When does the fiscal year end for Meridian Bioscience?
Meridian Bioscience's fiscal year ends in September. Where is Meridian Bioscience based?
Meridian Bioscience's address is: 3471 River Hills Drive, Cincinnati, OH, United States, 45244 What is Meridian Bioscience's ISIN number?
Meridian Bioscience's international securities identification number is: US5895841014 What is Meridian Bioscience's CUSIP number?
Meridian Bioscience's Committee on Uniform Securities Identification Procedures number is: 589584101
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert